Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Latest News
Cathie Wood buys $50.1 million of tumbling megacap stock
10 Stocks Make Up 60% of This $220 Billion Vanguard ETF. Here's What That Means If the AI Trade Cracks.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Is State Street SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
Should Vanguard Small-Cap Index Fund ETF Shares (VB) Be on Your Investing Radar?
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.crisprtx.com |
| Audit Risk | 8 |
| Board Risk | 8 |
| Overall Risk | 9 |
| Market Cap | 4.58B |
| Forward P/E | -11.97 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -6.17 |
| Forward EPS | -3.89 |
| Book Value | 18.83 |
| Price-to-Book | 2.47 |
| Enterprise-to-Revenue | 690.86 |
| Enterprise-to-EBITDA | -5.34 |
| Short Ratio | 11.26 |
| Earnings Date | 08/10/2026 |
| Earnings Call Date | |
| Earnings Average | -1.19 |
| Earnings Low | -1.44 |
| Earnings High | -0.81 |
| Revenue Average | 7.43M |
| Revenue Low | 0 |
| Revenue High | 31.30M |